Login
Alpha Cognition Inc. logo

Alpha Cognition Inc.

alphacognition.com

What Do They Do?

Develops and sells ZUNVEYL, an oral treatment for Alzheimer’s disease, to wholesalers and pharmacies, while developing other treatments for neurodegenerative diseases.

How Do They Make Money?

Wholesalers and pharmacies pay for ZUNVEYL when it is delivered. Licensing income comes from upfront payments, development or sales milestones, royalties, and sales of ingredients or finished goods to a partner.

revenue
SegmentShareRevenue
Product, net
Sold outright

66%
Licensing
34%

Who Are Their Customers?

Wholesalers and pharmacies buy ZUNVEYL directly; the company also works with a licensing and distribution partner for sales in parts of Asia, Australia and New Zealand.

Customers above 10% of revenue, FY2025
of revenue from three customers (48%, 22%, 17%)
FY2024: no customer at 10% or more of revenue

Do Revenues Turn Into Profits?

No. It lost $20.7M in FY2025.

Operating income, FY2025
−222% of revenue
▼ −89% (Loss) vs FY2024 (−$12M)
Net income, FY2025
−202% of revenue
▼ −40% (Loss) vs FY2024 (−$14.8M)
Free cash flow, FY2025
−202% of revenue
▼ −166% (Loss) vs FY2024 (−$7.8M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +174%
vs $2.8M in Q3 FY2025
Net income
▼ Turned to a loss
vs $574.4K in Q3 FY2025
Product, net share of revenue vs 82.2% in Q3 FY2025
  • Apr 10, 2026 Settled future payment obligations under a licensing agreement The company agreed to a one-time payment to extinguish remaining contingent royalty and milestone obligations.

Who Do They Compete With?

Competes with Eisai, Pfizer, Novartis, Janssen, Corium, and Biogen

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support